Rhythm Pharmaceuticals Inc (RYTM): Next-Year EPS Estimate 77.78%
As of 2026-08-26, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 77.78%. Featured in our EPS revision report on 2026-06-24.
On 2026-08-07, analyst consensus for RYTM's next-year EPS growth shifted from 77.75% to 77.78% — a positive change of 0.03 percentage points. The revised estimate has been sustained across 17 subsequent trading sessions. Current-year growth is projected at 3.45%.
What's Driving This
The primary driver is the analysts' upgrade of next-year EPS growth estimate from 74.71% to 77.75% on August 5, 2026. This follows positive clinical data presented at ENDO 2026, including interim Phase 2 results for setmelanotide in Prader-Willi syndrome, which likely prompted the upward revision. The stock continued to gain as the estimate edged up further to 77.78%, reflecting sustained momentum.
Generated 2026-08-13 from news as of 2026-08-13
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 77.78%
- EPS growth this year
- 3.45%
- EPS next quarter (est)
- -$0.72
- Last price
- $112.70
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-26 | 77.78% | 3.45% | -$0.72 | $112.70 |
| 2026-08-25 | 77.78% | 3.45% | -$0.72 | $113.35 |
| 2026-08-24 | 77.78% | 3.45% | -$0.72 | $111.44 |
| 2026-08-23 | 77.78% | 3.45% | -$0.72 | $110.00 |
| 2026-08-21 | 77.78% | 3.45% | -$0.72 | $110.00 |
| 2026-08-20 | 77.78% | 3.45% | -$0.72 | $108.92 |
| 2026-08-19 | 77.78% | 3.45% | -$0.72 | $115.73 |
| 2026-08-18 | 77.78% | 3.45% | -$0.72 | $115.25 |
| 2026-08-17 | 77.78% | 3.45% | -$0.72 | $115.44 |
| 2026-08-16 | 77.78% | 3.45% | -$0.72 | $115.48 |
| 2026-08-14 | 77.78% | 3.45% | -$0.72 | $115.48 |
| 2026-08-13 | 77.78% | 3.45% | -$0.72 | $116.02 |
| 2026-08-12 | 77.78% | 3.45% | -$0.72 | $117.60 |
| 2026-08-11 | 77.78% | 3.45% | -$0.72 | $112.85 |
| 2026-08-10 | 77.78% | 3.45% | -$0.72 | $115.48 |
| 2026-08-09 | 77.78% | 3.45% | -$0.72 | $115.63 |
| 2026-08-07 | 77.78% | 3.45% | -$0.72 | $115.63 |
| 2026-08-06 | 77.75% | 3.09% | -$0.73 | $112.10 |
| 2026-08-05 | 77.75% | 3.09% | -$0.73 | $110.71 |
| 2026-08-04 | 74.71% | 1.44% | -$0.75 | $105.78 |
| 2026-08-03 | 78.19% | -0.59% | -$0.81 | $102.78 |
| 2026-08-02 | 78.19% | -0.59% | -$0.81 | $99.25 |
| 2026-07-31 | 78.19% | -0.59% | -$0.81 | $99.25 |
| 2026-07-30 | 78.19% | -0.59% | -$0.81 | $105.74 |
| 2026-07-29 | 78.19% | -0.59% | -$0.81 | $106.53 |
| 2026-07-28 | 78.19% | -0.59% | -$0.81 | $108.04 |
| 2026-07-27 | 78.19% | -0.59% | -$0.81 | $106.13 |
| 2026-07-26 | 76.50% | -0.89% | -$0.81 | $102.10 |
| 2026-07-24 | 76.50% | -0.89% | -$0.81 | $102.10 |
| 2026-07-23 | 76.50% | -0.89% | -$0.81 | $102.66 |
Reports Featuring RYTM
Recent News
- Rhythm Pharmaceuticals, Inc. Q2 2026 Earnings Call SummaryMoby
- Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- The Battle Against Genetic Obesity Just Sent This Biotech Stock FlyingInvestor's Business Daily
- Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026GlobeNewswire
- Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi SyndromeGlobeNewswire
- Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business UpdateGlobeNewswire
- Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine SocietyGlobeNewswire
Screen Performance
Aggregate stats across all 2015 tickers our top-EPS-revision screen has flagged over the past 147 days.
- Median return since detection
- +3.0%
- % of tickers in the green
- 56%
- Median return on winners
- +20.0%
- Large revisions captured
- 1609
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Rhythm Pharmaceuticals Inc's next-year EPS growth estimate?▾
As of 2026-08-26, Rhythm Pharmaceuticals Inc (RYTM) has a next-year EPS growth estimate of 77.78%, based on analyst consensus.
When was the latest EPS estimate revision for RYTM?▾
The most recent revision occurred on 2026-08-07, when analysts adjusted the next-year EPS growth estimate from 77.75% to 77.78%.
What sector and industry does Rhythm Pharmaceuticals Inc belong to?▾
Rhythm Pharmaceuticals Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. RYTM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Rhythm Pharmaceuticals Inc (RYTM) appears here because it was detected by our daily top-EPS-revision-performer screen.